Q1 Earnings Estimate for CRBP Issued By HC Wainwright

Corbus Pharmaceuticals Holdings, Inc. (NASDAQ:CRBP) – Stock analysts at HC Wainwright issued their Q1 2025 earnings estimates for Corbus Pharmaceuticals in a note issued to investors on Thursday, November 7th. HC Wainwright analyst A. Maldonado expects that the biopharmaceutical company will post earnings of ($1.33) per share for the quarter. HC Wainwright has a “Buy” rating and a $80.00 price objective on the stock. The consensus estimate for Corbus Pharmaceuticals’ current full-year earnings is ($3.80) per share. HC Wainwright also issued estimates for Corbus Pharmaceuticals’ Q2 2025 earnings at ($1.40) EPS, Q3 2025 earnings at ($1.46) EPS and Q4 2025 earnings at ($1.54) EPS.

Other equities research analysts have also issued research reports about the company. Mizuho reissued an “outperform” rating and issued a $74.00 price objective on shares of Corbus Pharmaceuticals in a report on Friday, September 20th. Royal Bank of Canada restated an “outperform” rating and set a $82.00 price target on shares of Corbus Pharmaceuticals in a research note on Friday, September 20th. StockNews.com lowered shares of Corbus Pharmaceuticals from a “hold” rating to a “sell” rating in a research note on Saturday, August 10th. Oppenheimer increased their target price on Corbus Pharmaceuticals from $80.00 to $88.00 and gave the stock an “outperform” rating in a research report on Wednesday, August 7th. Finally, Wedbush reiterated an “outperform” rating and set a $51.00 price objective on shares of Corbus Pharmaceuticals in a research note on Monday, November 4th. One investment analyst has rated the stock with a sell rating, seven have issued a buy rating and one has issued a strong buy rating to the stock. According to MarketBeat, the stock presently has a consensus rating of “Moderate Buy” and an average price target of $65.86.

Corbus Pharmaceuticals Trading Down 1.0 %

Shares of NASDAQ CRBP opened at $18.59 on Monday. The stock has a fifty day simple moving average of $28.32 and a two-hundred day simple moving average of $41.93. Corbus Pharmaceuticals has a 1-year low of $3.03 and a 1-year high of $61.90. The firm has a market cap of $223.82 million, a price-to-earnings ratio of -3.97 and a beta of 2.56.

Institutional Inflows and Outflows

A number of institutional investors have recently added to or reduced their stakes in the company. Ikarian Capital LLC grew its position in Corbus Pharmaceuticals by 185.5% during the first quarter. Ikarian Capital LLC now owns 559,271 shares of the biopharmaceutical company’s stock valued at $21,946,000 after acquiring an additional 363,372 shares during the last quarter. Vanguard Group Inc. lifted its stake in Corbus Pharmaceuticals by 143.7% in the first quarter. Vanguard Group Inc. now owns 437,264 shares of the biopharmaceutical company’s stock worth $17,158,000 after purchasing an additional 257,808 shares during the last quarter. Janus Henderson Group PLC purchased a new stake in Corbus Pharmaceuticals during the first quarter valued at about $13,363,000. Darwin Global Management Ltd. bought a new position in shares of Corbus Pharmaceuticals during the second quarter valued at about $14,267,000. Finally, Price T Rowe Associates Inc. MD purchased a new position in shares of Corbus Pharmaceuticals in the first quarter worth about $7,554,000. Institutional investors own 64.64% of the company’s stock.

Insider Buying and Selling at Corbus Pharmaceuticals

In related news, major shareholder Cormorant Asset Management, Lp acquired 350,000 shares of the firm’s stock in a transaction that occurred on Friday, September 20th. The shares were bought at an average cost of $20.01 per share, for a total transaction of $7,003,500.00. Following the completion of the transaction, the insider now owns 2,375,000 shares in the company, valued at approximately $47,523,750. This trade represents a 0.00 % increase in their ownership of the stock. The acquisition was disclosed in a filing with the Securities & Exchange Commission, which is available through this hyperlink. Insiders own 4.00% of the company’s stock.

Corbus Pharmaceuticals Company Profile

Corbus Pharmaceuticals Holdings, Inc, a biopharmaceutical company, develops products to defeat serious illness. It develops CRB-701, an antibody drug conjugate (ADC) that targets the expression of Nectin-4 on cancer cells to release a cytotoxic payload of monomethyl auristatin E (MMAE), which is in Phase I clinical trial; CRB-601, an anti-integrin monoclonal antibody that blocks the activation of TGFß expressed on cancer cells for the treatment of solid tumors; CRB-913, a peripherally restricted cannabinoid type-1 (CB1) receptor inverse agonist for the treatment of obesity.